OpenURL Connection Search

Select item for more details and to access through your institution.

Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.
Published in:
Breast Cancer Research & Treatment, 2021, v. 189, n. 2, p. 521, doi. 10.1007/s10549-021-06304-6
By:
- Kleckner, Ian R.;
- Jusko, Todd A.;
- Culakova, Eva;
- Chung, Kaitlin;
- Kleckner, Amber S.;
- Asare, Matthew;
- Inglis, Julia E.;
- Loh, Kah Poh;
- Peppone, Luke J.;
- Miller, Jessica;
- Melnik, Marianne;
- Kasbari, Samer;
- Ossip, Deborah;
- Mustian, Karen M.
Publication type:
Article
Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer.
Published in:
Cancer (0008543X), 2018, v. 124, n. 15, p. 3118, doi. 10.1002/cncr.31552
By:
- Sanoff, Hanna K.;
- Goldberg, Richard M.;
- Ivanova, Anastasia;
- O'Reilly, Seamus;
- Kasbari, Samer S.;
- Kim, Richard D.;
- McDermott, Ray;
- Moore, Dominic T.;
- Zamboni, William;
- Grogan, William;
- Cohn, Allen Lee;
- Bekaii‐Saab, Tanios S.;
- Leonard, Gregory;
- Ryan, Theresa;
- Olowokure, Olugbenga O.;
- Fernando, Nishan H.;
- McCaffrey, John;
- El‐Rayes, Bassel F.;
- Horgan, Anne M.;
- Sherrill, Gary Bradley
Publication type:
Article
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Published in:
2018
By:
- Sanoff, Hanna K;
- Goldberg, Richard M;
- Ivanova, Anastasia;
- O'Reilly, Seamus;
- Kasbari, Samer S;
- Kim, Richard D;
- McDermott, Ray;
- Moore, Dominic T;
- Zamboni, William;
- Grogan, William;
- Cohn, Allen Lee;
- Bekaii-Saab, Tanios S;
- Leonard, Gregory;
- Ryan, Theresa;
- Olowokure, Olugbenga O;
- Fernando, Nishan H;
- McCaffrey, John;
- El-Rayes, Bassel F;
- Horgan, Anne M;
- Sherrill, Gary Bradley
Publication type:
journal article

Found: 3

Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer.

Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.